DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up
Portfolio Pulse from Lara Goldstein
Algernon Pharmaceuticals' subsidiary, Algernon NeuroScience, has completed dosing the final cohort of its Phase 1 clinical study for its DMT compound, AP-188, aimed at treating stroke and Traumatic Brain Injury (TBI). The study found no safety or tolerability issues, and the company plans to accelerate its Phase 2 studies for both stroke and TBI.
June 05, 2023 | 5:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Algernon Pharmaceuticals' Phase 1 clinical study for its DMT compound, AP-188, has successfully completed dosing, with no safety or tolerability issues. The company plans to accelerate Phase 2 studies for stroke and TBI treatment.
The successful completion of Phase 1 dosing for Algernon Pharmaceuticals' DMT compound, AP-188, indicates progress in the development of a treatment for stroke and TBI. This positive news is likely to have a short-term positive impact on the company's stock price, as it demonstrates progress in their clinical trials and brings them closer to potentially bringing a new treatment to market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100